** Shares of surgical factory operator Surgery Partners SGRY.O rise 3.8% to $23 after Q1 results
** Co's Q1 revenue rises 8.2% to $776 mln from a year-ago
** Adj. EBITDA up 6.6% to $103.9 mln
** CFO Dave Doherty says Q1 results increase confidence to reaffirm FY guidance, amid uncertainty
** Nine out of 12 analysts rate stock "buy" or higher, three "hold"; Median PT is $33 - LSEG
** With session moves, SGRY up 9.4% YTD vs a 3.9% decline in the Nasdaq .IXIC
(Reporting by Twesha Dikshit)
((Twesha.Dikshit@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。